Death triggers pause of 2seventy CAR-T cell therapy leukemia trial

Investigators have paused an early-phase trial of 2seventy bio’s CD33-targeted CAR-T cell therapy after a patient died. The acute myeloid leukemia (AML) patient was the first person treated in the second dose cohort of the phase 1 clinical trial.